Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

ELYM Financial Statements and Analysis

NASDAQ : ELYM

Eliem Therapeutics, Inc.

$5.11
-0.05-0.97%
At Close 4:00 PM
Not Actively Trading
57.73
BESG ScoreESG Rating

ELYM FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

ELYM Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateJun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
revenue00000
cost of revenue00000
gross profit00000
gross profit ratio00000
research and development expenses1.046M1.091M3.127M2.876M3.688M
general and administrative expenses3.667M1.914M1.995M2.125M3.026M
selling and marketing expenses00000
selling general and administrative expenses3.667M1.914M1.995M2.125M3.026M
other expenses1.485M0-2.258M01.11M
operating expenses4.713M3.005M5.122M5.001M6.714M
cost and expenses4.713M3.005M5.122M5.001M6.714M
interest income01.341M1.349M1.261M1.11K
interest expense001.148M00
depreciation and amortization03.005M3.055K4.779K-384.00K
ebitda-56.372M-3.005M-5.122M-5.001M-7.098M
ebitda ratio00000
operating income-4.713M-3.005M-5.122M-5.001M-6.714M
operating income ratio00000
total other income expenses net-50.176M1.308M1.481M1.033M1.494M
income before tax-54.889M-1.697M-3.641M-3.968M-5.22M
income before tax ratio00000
income tax expense0-3.005M-3.055K-4.779K0
net income-54.889M-1.697M-3.641M-3.968M-5.22M
net income ratio00000
eps-1.81-0.061-0.13-0.15-0.19
eps diluted-1.81-0.061-0.13-0.15-0.19
weighted average shs out30.35M27.639M27.699M27.071M26.841M
weighted average shs out dil30.35M27.639M27.699M27.071M26.841M
Graph

ELYM Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateJun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
cash and cash equivalents223.14M105.031M93.112M57.353M25.294M
short term investments0013.686M50.08M77.339M
cash and short term investments223.14M105.031M106.798M107.433M102.633M
net receivables02.021M2.024M1.922M6.865M
inventory0002.478M4.117M
other current assets3.16M2.171M1.433M601.00K629.00K
total current assets225.997M108.271M110.255M112.434M114.244M
property plant equipment net21.00K111.00K199.00K286.00K372.00K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets-1.00952.00K14.999K15.00K1.658M
total non current assets20.999K1.063M213.999K301.00K2.03M
other assets1.0001.0000
total assets226.018M109.334M110.469M112.735M116.274M
account payables509.00K85.00K66.00K736.00K878.00K
short term debt200.00K225.00K334.00K401.00K485.00K
tax payables00000
deferred revenue-509.00K-85.00K-66.00K00
other current liabilities3.032M2.64M2.499M1.764M2.255M
total current liabilities3.741M2.95M2.833M2.901M3.618M
long term debt0015.00K58.00K100.00K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities0021.999K34.00K55.00K
total non current liabilities0036.999K92.00K155.00K
other liabilities001.0000
capital lease obligations100.00K225.00K15.00K459.00K585.00K
total liabilities3.741M2.95M2.87M2.993M3.773M
preferred stock00000
common stock7.00K3.00K3.00K3.00K3.00K
retained earnings-212.565M-157.676M-155.979M-152.338M-148.37M
accumulated other comprehensive income loss00-2.00K-11.00K-35.00K
other total stockholders equity434.835M264.057M263.577M262.088M260.903M
total stockholders equity222.277M106.384M107.599M109.742M112.501M
total equity222.277M106.384M107.599M109.742M112.501M
total liabilities and stockholders equity226.018M109.334M110.469M112.735M116.274M
minority interest00000
total investments0013.686M50.08M77.339M
total debt100.00K225.00K349.00K459.00K585.00K
net debt-223.04M-104.806M-92.763M-56.894M-24.709M
Graph

ELYM Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateJun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
deferred income tax00000
stock based compensation512.00K465.00K1.202M656.00K777.00K
change in working capital1.98M-640.00K1.421M7.473M-2.672M
accounts receivables00000
inventory00000
accounts payables-1.175M20.00K-672.00K-142.00K14.00K
other working capital1.98M-640.00K2.093M7.615M-2.686M
other non cash items52.242M518.00K71.00K-671.00K-850.00K
net cash provided by operating activities-667.00K-1.819M-947.00K3.49M-7.965M
investments in property plant and equipment00000
acquisitions net-4.645M0000
purchases of investments00-1.00K-2.463M-38.533M
sales maturities of investments013.751M36.749M30.50M36.932M
other investing activites-5.00M13.751M000
net cash used for investing activites-9.645M13.751M36.748M28.037M-1.601M
debt repayment00000
common stock issued128.402M15.00K288.00K528.00K24.00K
common stock repurchased00000
dividends paid00000
other financing activites015.00K0024.00
net cash used provided by financing activities128.402M15.00K288.00K528.00K24.00K
effect of forex changes on cash19.00K-28.00K-330.00K4.00K399.00K
net change in cash118.109M11.919M35.759M32.059M-9.143M
cash at end of period223.14M105.031M93.112M57.353M25.294M
cash at beginning of period105.031M93.112M57.353M25.294M34.437M
operating cashflow-667.00K-1.819M-947.00K3.49M-7.965M
capital expenditure00000
free cash flow-667.00K-1.819M-947.00K3.49M-7.965M
Graph

Frequently Asked Questions

How did Eliem Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, ELYM generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Eliem Therapeutics, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Eliem Therapeutics, Inc. reported a $0.00 Gross Profit for the quarter ended Jun 30, 2024.
Have ELYM's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. ELYM incurred $4.71M worth of Operating Expenses, while it generated -$4.71M worth of Operating Income.
How much Net Income has ELYM posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Eliem Therapeutics, Inc., the company generated -$54.89M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Eliem Therapeutics, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Eliem Therapeutics, Inc. as of the end of the last quarter was $223.14M.
What are ELYM's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, ELYM had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Eliem Therapeutics, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of ELYM were $226.00M, while the Total Assets stand at $226.02M.
As of the last quarter, how much Total Debt did Eliem Therapeutics, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of ELYM's debt was $100.00K at the end of the last quarter.
What were ELYM's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, ELYM reported total liabilities of $3.74M.
How much did ELYM's Working Capital change over the last quarter?
Working Capital Change for ELYM was $1.98M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
ELYM generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. ELYM generated -$667.00K of Cash from Operating Activities during its recently reported quarter.
What was ELYM's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. ELYM reported a $118.11M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph